Welcome Italia selects ADVA FSP 3000 for ultra-high-capacity enterprise services
30.7.2019 09:55:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Welcome Italia has selected its FSP 3000 and ALM fiber monitoring solution to enable assured high-capacity enterprise services throughout Italy. The technology partnership will create scalable fiber optic infrastructure and provide the security and reliability needed for IoT and 5G applications. Stretching over 2,500km and connecting Welcome Italia’s two main data centers, the new network features ADVA’s colorless, directionless and flexgrid multi-degree ROADMs, enabling automatic traffic rerouting for enhanced availability. The solution has also been primed for the comprehensive, low-latency security of ADVA’s ConnectGuard™ Optical encryption technology. ADVA’s partner Sirti is installing the network and will also provide ongoing maintenance and support.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190729005500/en/
Image ADVA's FSP 3000 and ALM fiber monitoring solution will play a key role in delivering assured high-capacity enterprise services throughout Italy (Photo: Business Wire)
”Our aim is to harness the best technology available to provide the ultimate service for our enterprise customers. ADVA’s scalable and efficient solution not only empowers us to deliver fast, flexible and secure business continuity services, but it also helps us reduce cost and lay the foundation for future growth,” commented Nicola Gallico, network manager and founder, Welcome Italia. “This deployment provides concrete answers to the most urgent needs of Italian enterprises. It means they can rely on high-speed, low-latency connectivity backed up by a fully redundant network architecture and protected by real-time fiber monitoring. With the support of the ADVA and Sirti team, we’ll continue to help our customers develop their businesses and seize new opportunities.”
Welcome Italia’s new backbone network serves enterprise clients throughout Italy with points of presence spread across the country. Built on the ADVA FSP 3000, it simplifies network operations and helps to reduce capital and operational expenditure. With its modular architecture, the FSP 3000 gives Welcome Italia the freedom to expand its network as soon as it’s required. The solution is also monitored by the ADVA ALM, which gives real-time insight into the integrity and performance of Welcome Italia’s fiber infrastructure, significantly improving robustness and efficiency. What’s more, the complete network is managed by Ensemble Controller, which combines efficiency in manual operations with programmatic control. This advanced management and domain control solution supports users while also enabling intelligent algorithms to gather data and take autonomous action.
“Welcome Italia chose our technology because it’s the ideal tool for meeting the needs of enterprise customers. It provides superb scalability and cost efficiency, enabling high-speed services that are secure and fully future proof. We’re pleased to be working closely with Welcome Italia’s team to ensure that businesses in this region can capitalize on the most advanced latency-sensitive applications as soon as they hit the market,” commented Marcello Forti, VP, sales, ADVA. “With the flexibility of our ROADM technology and our ALM providing complete fiber network visibility, this solution gives Welcome Italia a new level of agility and reliability. For enterprises across Italy, Welcome Italia’s new network will be the key to harnessing the business opportunities of the IoT.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.
About Welcome Italia
Welcome Italia is an Italian telecommunication operator that simplifies your company’s communications with an integrated offer of mobile and fixed line services called Vianova. Vianova combines traditional services, like telephony and ultra-broadband data access, with unified communication and collaboration services like cloud, centrex, mail, meetings, Wi-Fi calls, busy calls, SIM manager. Welcome Italia is also appreciated for the quality of its customer care that answers calls in three rings. Two property data centers host the redundant infrastructure that allows the supply of services for the whole Welcome Italia Group. www.welcomeitalia.it/en
Published by:
ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190729005500/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
